MeiraGTx Holdings plc (NasdaqGS: MGTX)
Health Care · Biotechnology · US
$10.69
-0.93% today · +36.5% 1Y
MeiraGTx Holdings plc (NasdaqGS: MGTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.03B and employs 393 people.
Over the last twelve months the share price has gained 36.5%, trading between 6.62 and 15.35.
Tweenvest scores MeiraGTx Holdings plc across four factors: quality 35/100, value 30/100, growth 100/100. Its strongest factor is growth.
MGTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.03B
- Revenue (TTM)
- $397.50M
- P/E
- 11.39
- EPS
- 0.94
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $15.35
- 52-week low
- $6.62
- Avg volume (3M)
- —
- Shares outstanding
- 96.04M
- Employees
- 393
- Next earnings
- —
About MeiraGTx Holdings plc
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
- ISIN
- KYG596651029
- Founded
- 2015
- Listed since
- Jun 8, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chengdu Kanghua Biological Products Co., Ltd.SZSE: 300841 | $1.07B | CN¥55.26 | -1.95% |
| Beijing Strong Biotechnologies,Inc.SZSE: 300406 | $1.06B | CN¥12.14 | +1.68% |
| MannKind CorporationNasdaqGM: MNKD | $1.06B | $3.29 | -13.42% |
| CStone PharmaceuticalsSEHK: 2616 | $1.03B | HK$5.09 | -9.99% |
| Immatics N.V.NasdaqCM: IMTX | $1.02B | $7.43 | -2.11% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $1.01B | ₩16,030.00 | -0.62% |
| Aktis Oncology, Inc.NasdaqGS: AKTS | $1.01B | $18.15 | +2.31% |
| Adlai Nortye Group Ltd.NasdaqGM: ANL | $1.01B | $15.62 | +3.51% |
Figures last refreshed Oct 11, 2026.